|
|
AS-2 vaccine adjuvant |
|
Vaxjo ID |
91 |
|
Vaccine Adjuvant Name |
AS-2 vaccine adjuvant |
|
Alternative Names |
SBAS2, SmithKline Beecham adjuvant system 2 |
|
Adjuvant VO ID |
VO_0001336
|
|
Description |
SmithKline Beecham adjuvant system 2 : is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion (Euroconferences). |
|
Stage of Development |
Clinical Trial |
|
Components |
QS-21, MPL, and emulsion |
|
Function |
SBAS2 was carefully designed and shown to induce very strong antibody responses, strong effector cellular immune response (TH1 primarily) and DTH responses, as well as MHC class I restricted CTL responses. This adjuvant while clearly more potent than alum is also more reactogenic. It it however still compatible with widespread use in humans, either for the prevention of severe, otherwise unpreventable diseases todate (Malaria, HIV...) or for the treatment of already established infectious or non infectious diseases, such as chronic hepatitis B, chronic HPV infections, and cancer (Euroconferences). |
| Related Vaccine(s) |
|
| References |
Ayyoub et al., 2003: Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Liénard D, Speiser DE. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(2); 669-677. [PubMed: 12576434].
Euroconferences: New trends in vaccine R & D: Adjuvants, delivery systems and antigen formulations [http://www.pasteur.fr/applications/euroconf/vaccins/vaccins-abs.html]
|
|
